• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Merck bets big on oral PCSK9 inhibitor, putting 6-year outcome study at heart of phase 3...

cafead

Administrator
Staff member
  • cafead   Aug 25, 2023 at 10:22: AM
via Merck & Co. is betting big on its oral PCSK9 inhibitor. Buoyed by midphase results, the Big Pharma has kicked off a clutch of late-stage studies including a cardiovascular outcomes trial that will follow patients for around six years.

article source
 

<